Robin Mansukhani, CEO of Deciduous Therapeutics, presents a cutting-edge discussion on harnessing the immune system to address the accumulation of senescent cells and treat diseases of aging. He highlights innovative therapeutic approaches to restore healthspan and address systemic aging effects.

Key Points:

Mansukhani’s work showcases the promise of leveraging immune mechanisms to counteract senescence and improve healthspan, highlighting the potential to revolutionize aging treatments. Restoring the immune system’s natural ability to remove senescent cells is a game-changer in treating aging-related diseases and improving quality of life.

• Immune System as a Pillar of Health: Mansukhani underscores the importance of the immune system in healthspan regulation, emphasizing that immune function peaks in the 20s and steadily declines. Restoring immune functionality offers a natural and effective way to combat aging and its associated diseases.
• Senescent Cells and Immune Failure: Senescent cells, which are permanently damaged and inflammatory, accumulate due to declining immune clearance. This accumulation drives chronic inflammation, fibrosis, and stem cell dysfunction, exacerbating age-related diseases.
• Harnessing Natural Killer T (NKT) Cells: Mansukhani's team identified NKT cells as key players in removing senescent cells. By restoring NKT cell activity, they achieved significant reductions in senescent cells and improved disease outcomes in preclinical models.
• Single-Dose Therapeutic Efficacy: A novel single-dose therapy was shown to reduce fibrosis in lung tissue by 75-80% and improve insulin resistance and glucose tolerance in diabetic models. This approach exemplifies the potential of intermittent, highly effective treatments.
• A Paradigm Shift in Medicine: The therapy’s systemic impact, safety at high doses, and ability to target multiple aging-related conditions mark a shift in how we approach chronic diseases, making treatments more accessible and cost-effective globally.